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For isotoxic conformal radi-
ation therapy of lung tumors,
improved absolute dose
coverage of the planning
target volume is obtained by
use of a 2-mm multileaf
collimator margin, despite
penumbra broadening in
lung. This result applies to a
range of tumor sizes and
positions, and is robust to
respiration-induced tumor
movement, provided that
patient setup margins
included in the planning
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http://dx.doi.org/10.1016/j.ijrobp.2013.12.034Purpose: Isotoxic dose escalation schedules such as IDEAL-CRT [isotoxic dose escalation and
acceleration in lung cancer chemoradiation therapy] (ISRCTN12155469) individualize doses
prescribed to lung tumors, generating a fixed modeled risk of radiation pneumonitis. Because
the beam penumbra is broadened in lung, the choice of collimator margin is an important
element of the optimization of isotoxic conformal radiation therapy for lung cancer.
Methods and Materials: Twelve patients with stage I-III non-small cell lung cancer (NSCLC)
were replanned retrospectively using a range of collimator margins. For each plan, the pre-
scribed dose was calculated according to the IDEAL-CRT isotoxic prescription method, and
the absolute dose (D99) delivered to 99% of the planning target volume (PTV) was determined.
Results: Reducing the multileaf collimator margin from the widely used 7 mm to a value of
2 mm produced gains of 2.1 to 15.6 Gy in absolute PTV D99, with a mean gain  1 standard
error of the mean of 6.2  1.1 Gy (2-sided P<.001).
Conclusions: For NSCLC patients treated with conformal radiation therapy and an isotoxic
dose prescription, absolute doses in the PTV may be increased by using smaller collimator
margins, reductions in relative coverage being offset by increases in prescribed dose.
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Outcomes after standard radiation therapy of stage IIB-III non-
small cell lung cancer (NSCLC) are poor. However, dose escala-
tion can be achieved with acceptable toxicity, even when radiation
therapy is combined with sequential or concurrent chemotherapy,
potentially leading to improved local control (1-3). Presently it is
unclear whether overall survival is improved by dose escalation
delivered by extended length schedules (4, 5), but outcomes do
appear to improve when escalation is achieved by use of accel-
erated, isotoxic protocols. Results from a study of individualized
radiation dose escalation in the setting of sequential chemo-
radiation show an increase in median survival from 17.5 months to
23.6 months in comparison with standard treatment (2), while
recent published data show a 2-year survival rate of 67% for
concurrent chemoradiation with individualized dose escalation
(3). In the United Kingdom, trials of accelerated isotoxic radia-
tion dose escalation of sequential chemoradiation (I-START,
ISRCTN74841904) and concurrent chemoradiation isotoxic dose
escalation and acceleration in lung cancer chemoradiation therapy
(IDEAL-CRT, ISRCTN12155469) have been initiated (6). In these
studies, tumor dose is prescribed on the basis of the lung dose
distribution, subject to minimum and maximum limits and addi-
tional doseevolume constraints for cord, esophagus, and brachial
plexus.
The low-density lung tissue surroundingNSCLC tumors reduces
the target dose coverage achievable using conventional field edge
placement. Matching of the 95% (of prescribed dose) isodose con-
tour to the edge of a planning target volume (PTV) located in lung
requires field sizes to be increased by at least 1 cmbeyond those used
when the PTV is located in unit density tissue (7), but these larger
fields raise doses in the surrounding lung tissue, limiting the degree
of dose escalation that can be safely achieved. Engelsman et al (8)
explored the idea of increasing the probability of lung tumor con-
trol by shrinking field sizes so that the 95% isodose shifts inside the
PTV, thus reducing target coverage but allowing higher doses to be
prescribed. Tests on a simple phantom geometry and a single patient
dataset showed that significant improvements in the equivalent
uniform dose and minimum dose within the clinical target volume
could be obtained by use of this approach, suggesting that tumor
control is not always maximized by limiting PTV doses to liewithin
95% and 107% of the prescribed dose.
In fact, more heterogeneous PTV dose distributions are used in
stereotactic body radiation therapy (SBRT) of small lung lesions.
An investigation of optimal collimator (beam) margins for lung
SBRT found that the choice of margin (determined from Monte
Carlo dose calculations) depended on tumor size and lung density
but was in the range of 0 to 5 mm (9).
In this work, we investigated the impact of multileaf collimator
(MLC) margin on absolute dose coverage of the PTV achieved
by conformal radiation therapy of NSCLC, isotoxically escalated
according to the IDEAL-CRT protocol (10). In particular we
explored whether a single optimal collimator margin can be
identified for a range of tumor sizes and locations.Methods and Materials
The work was performed in 2 stages. First, we carried out a
planning study to determine optimal margins for a range of
patients. Second, we used a simplified phantom to evaluate thedosimetric effects of respiratory movement of the dense tumor
volume within lung, and of changes in surrounding lung density,
to determine the impact these effects may have on the choice of
collimator margin.
Patient datasets and contours
Coregistered free-breathing 3-dimensional computed tomography
(3D-CT) and 10-phase 4-dimensional CT images of 12 NSCLC
patients were used in this retrospective replanning study (Table 1).
Scans were acquired during quiet breathing, with a slice thickness
of 0.25 cm. All patients had given written consent for their images
to be used for research purposes. For each patient, the gross tumor
volume (GTV) was delineated on the 4D-CT exhale and inhale
phases, and these 2 volumes were combined on the free-breathing
scan to create a merged target volume. A microscopic spread
margin of 7 mm was then applied to the merged volume to create
an internal target volume (ITV), and a further patient setup error
margin of 5 mm was added to create the PTV. Thus, the total
merged GTV-PTV margin was 12 mm, according to our local
protocol, slightly larger than the 10 mm minimum total margin
specified in the IDEAL-CRT guidelines. Normal lung was defined
as total lung volume minus GTVas observed on the free-breathing
CT, to model pneumonitis risk. In practice, not all the patients in
Table 1 would be treated according to the IDEAL-CRT protocol,
which is focused on patients with stage II-III disease, but they
were included in this planning study to demonstrate trends for a
wide range of tumor locations and field sizes.
Treatment planning
The 3D conformal radiation therapy (3D-CRT) plans were created
on the free-breathing CTs of each patient, using 4 or 5 fields
entering patients on the same side as the tumor and spanning an
average angular range of 230. The doses were calculated on a
standard 2.5-mm grid (compatible with the 2.5-mm CT slice
thickness) by use of the convolution-superposition algorithm
(AAA, anisotropic analytical algorithm) and grid-based Boltz-
mann solver (Acuros, AXB) supplied in release 10.0.28 of
Eclipse, version 10 (Varian, Palo Alto, CA). Although AAA is
used extensively to plan clinical treatments, moderate differences
have been reported between AAA and Monte Carlo dose calcu-
lations in normal-density and low-density lung (2%-4% and 12%,
respectively), whereas differences between AXB and Monte Carlo
doses are small (<2%) for both normal-density and low-density
lung (11). We have therefore recalculated treatment plans using
the AXB algorithm, with monitor units fixed at the values used in
AAA plans, to check dosimetric accuracy in the presence of lung
tissue.
Initially, a collimator margin of 7 mm was set from the edge of
the PTV to the midpoint of each leaf of the MLC in the beam’s
eye views of each field, consistent with values used when the
tumor is surrounded by unit density material (12). When doses
were calculated by use of the AAA algorithm, this margin allowed
plans to be generated with an average 92.5% coverage (range,
82.7%-98.9%) of the PTV by 95% of the isocenter dose while
limiting maximum PTV doses to less than 107%. Before isotoxic
dose escalation, each plan was prescribed an initial dose of 68 Gy
in 30 fractions at the isocenter, copied and recalculated for
different collimator margins but the same dose prescription.
Table 1 GTV sizes and TNM stages for patients in this retrospective planning study, listed in order of increasing tumor size
Patient TNM Stage Position Motion (cm)* GTV (cm3) PTV (cm3) Lung-GTV(cm3)
Field size
X  Y (cm)y
Mean lung
EQD (Gy)z
1 TxN2M0 III A Mediastinum 0.7 8.9 102.9 4118 7.7  7.0 7.3
2 T1aN0M0 I A L lingual 0.7 11.5 111.7 4776 7.2  7.8 9.4
3 TxN2M0 III A Mediastinum 0.3 13.5 105.9 2897 8.5  6.7 9.8
4 T1bN2M0 III A R upper 0.3 26.6 208.7 2717 9.2  9.2 18.9
5 T2aN1M0 II A R mid 1.0 29.9 191.7 3033 8.3  8.9 16.2
6 T2aN2M0 III A R upper 0.7 36.4 244.1 4331 10.6  8.1 14.5
7 T2aN2M0 III A L lower 0.6 49.6 258.4 2524 8.4  10.9 20.8
8 T2aN0M0 I B R lower 1.2 69.4 380.7 4933 10.4  9.3 17.2
9 T2aN1M0 II A L upper 0.8 84.0 396.4 4571 11.3  9.7 16.8
10 T2bN1M0 II B R mid 0.4 94.1 330.7 3035 10.4  9.4 15.8
11 T4N0M0 III A R upper 0.1 122.1 524.0 3990 11.4  10.4 21.2
12 T3N0M0 II B R lower 1.4 177.2 736.4 4342 15.4  11.4 22.9
Abbreviations: EQD Z mean equivalent dose in 2 Gy fractions delivered to the lung; GTV Z gross tumor volume; PTVZ planning target volume.
* Maximum displacement of the GTV in the cranialecaudal direction observed in different phases of 4-dimensional computed tomography.
y Smallest field size for the 7-mm margin reference plan.
z Mean lung dose (Gy) to the lung-GTV volume for a 7-mm margin plan with 68 Gy prescribed to the isocenter.
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Isotoxic dose prescription aims to achieve the same modeled risk
of radiation pneumonitis for each patient (3, 6, 13), calculated via
the mean equivalent dose in 2 Gy fractions delivered to the lung
(EQD2) computed from the (lung-GTV) differential doseevolume
histogram (DVH) (14). The patient-specific dose escalation
regimen used in the IDEAL-CRT trial has been described previ-
ously (13, 15), and is illustrated in Schema E1 (available at www.
redjournal.org).
After calculation of an initial plan, the prescribed dose (PD)
was escalated to generate a fixed normal lung mean EQD2 level of
18.2 Gy. This dose was reduced by 10% to allow for any effect of
concurrent chemoradiation, and constrained by the requirement
that (lung-GTV) V20 is less than 35%. Isotoxic prescribed doses
were calculated for the each plan, and tumor dose coverage was
assessed using the absolute isotoxic PTV D99 metric (absolute
dose to the hottest 99% of the PTV). Patient-by-patient paired
differences between isotoxic PTV D99 values obtained for each
collimator margin versus a 7-mm margin were quantified (tabu-
lating mean differences  standard errors of the mean [SEM] for
all patients) and their significance was assessed by use of Student t
test.
In IDEAL-CRT, dose is limited by other normal tissue con-
straints (cord, D0.1cc<47 Gy; brachial plexus, D30%<60 Gy, D0.1cc
<65 Gy; heart, D100% <45 Gy, D67% <53 Gy, D33% <60 Gy;
esophagus, D1cc <65, 68, 71 Gy; 6þ6 trial design) and is restricted
to the range of 63 to 73 Gy. Because we wished to specifically
investigate tradeoffs between PTV coverage and lung dose in this
study, the dose constraints on normal tissues (cord, esophagus,
brachial plexus) and the IDEAL-CRT upper and lower limits on
prescribed dose were not applied initially.
Phantom dataset
The phantom contains a lung insert in which a 40-mm diameter
cylindrical tumor-like structure (GTV) can be located at 4
different positions (Fig. 1) to approximate different phases of the
breathing cycle. The total range of tumor positions was 25 mm inthe cranialecaudal direction and 5 mm anterioreposterior, which
represents a larger amplitude of respiratory movement than that
seen in patients analyzed in this study (Table 1). The lung material
was initially assigned 719 Hounsfield units (HU) (normal-den-
sity lung) in all 4 phases, and subsequently 950 HU (low-density
lung) to explore the effects of lung density on the dose distribution
during respiration. The material used to represent the tumor was
assigned 0 HU. We also determined the effect of carrying out
calculations on a 1-mm dose grid.Results
Optimal isotoxic collimator margin
Decreasing the MLC margin reduced the relative PTV dose
coverage but also increased the absolute IDEAL-CRT isotoxic
prescribed doses (which for the moment we did not limit to 63-
73 Gy). The overall result was that as the collimator margin was
reduced from 7 mm to 2 mm, absolute isotoxic PTV D99 values
rose-reductions in relative D99 being more than offset by in-
creases in prescribed dose. However, reducing the collimator
margin further, below 1 mm, led to a rapid drop-off in the ab-
solute dose coverage of the PTV. Data are shown in Figure 2 for
patient 7, whose tumor had a volume in the middle of the range
studied here. For this patient, reducing the collimator margin
from 7 mm to 2 mm led to an increase in prescribed dose from
60.2 Gy to 70.9 Gy, and a net gain of 4.7 Gy in absolute PTV D99
dose.
The variation of absolute PTV D99 with collimator margin is
shown in Figure 3a for all 12 patients. A margin of 2 mm is
optimal, independent of tumor volume, field size or tumor
movement; the average optimal margin value worked out at
1.7 mm  0.2 mm according to the AAA algorithm and
2.0 mm  0.2 mm according to AXB. Figure 3b shows the means
(1 SEM) of patient-by-patient paired differences between ab-
solute D99 levels achieved by use of various collimator margins
versus a 7-mm margin. Gains in D99 ranged between 2.1 and
15.6 Gy, with a mean of 6.2  1.1 Gy SEM. (2-sided P<.001) and
Fig. 1. The gross tumor volume (GTV) is represented by a 40-mm diameter cylinder of unit density, located at 4 different positions,
roughly simulating movement during the breathing cycle. (a-c) Coronal views show the GTV at its inferiormost, mid, and superiormost
positions. The planning target volume created by merging the GTVs and applying margins is shown as a white line. The GTV can occupy 2
positions at its inferiormost extent, 1 sited 5 mm posterior to the other positions, as shown in magnified sagittal image (d).
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PDs could be delivered to patients with smaller tumors (patients
1-3 in Fig. 3a) or with centrally located or upper-lobe tumors
(Table 1). However, these patients may in practice be candidates
for SBRT, and we therefore reanalyzed the data for patients 4 to 12
only (Fig. 3c). For this subset, a smaller gain in mean dose of
4.4  0.4 Gy (2-sided P<.001) was achieved by reducing the
collimator margin from 7 mm to 2 mm, but a gain of 2.1 Gy was
achieved for even the largest tumor volume (patient 12). In
addition, for this patient the PD of 63 Gy delivered using a 7-mm
collimator margin was associated with a (lung-GTV) V20 of
38.7%, making the patient ineligible for dose escalation, whereas
with the use of a 2-mm collimator margin, a PD of 63 Gy was
associated with V20 of 34.9%, within the normal tissue constraints
of the IDEAL-CRT protocol.
Effect of dose calculation algorithm
The influence of the dose calculation algorithm on the optimum
collimator margin was studied for all patients. Coverage of the30
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Fig. 2. Variation of absolute planning target volume D99 dose
with collimator margin plotted for patient 7. Prescribed doses
(PD) and relative coverage (D99 [%]) are also shown. Black and
gray lines represent calculations made using the anisotropic
analytical and Acuros algorithms, respectively.PTV by the 95% isodose contour was substantially higher in
plans initially calculated using AAA than in those recalculated
using the AXB algorithm (80.8% vs 92.5%). However, the dif-
ferences between mean lung EQD2s calculated by the 2 dose
calculation algorithms were much smaller, the largest observed
difference (AAA-AXB) being 0.3 Gy for patient 12, as were
the associated differences in isotoxically prescribed doses, the
maximum PD difference (AAA-AXB) of þ0.84 Gy also being
observed for patient 12. The D99 coverage values obtained by
use of the AAA algorithm were slightly higher than those ob-
tained using the AXB (on average by 0.7%). However, this
improved coverage was seen across the range of collimator
margins (Fig. 2, patient 7); therefore, although the AAA algo-
rithm predicted a higher absolute D99 for the 2-mm margin than
did AXB, the same collimator margin value was optimal for both
dose algorithms studied.
Phantom study of dosimetric changes induced by
respiratory motion
Analysis of plans calculated on the static phantom, set up with the
GTV located at each of its 4 positions within the lung insert,
shows that for the same treatment plan, variations in PTV D99
dose induced by changes in tumor location within the PTV were
less than 1.5% (Fig. 4). This was true for the 7-mm and 2-mm
collimator margins (Table 2, Fig. 3) irrespective of the dose
calculation algorithm and grid used. The reduction in PTV D99
dose when different densities were assigned to the surrounding
lung tissue were also within 1% when 7-mm and 2-mm margin
plans were compared, indicating that the optimum margin value of
2 mm is valid for both normal-density and low-density lung (Table
E1, available at www.redjournal.org).
Discussion
For the specific isotoxic escalation scheme and the patients
studied here, a mean gain in PTV D99 of 6.2 Gy (range, 2.1-
15.6 Gy) could be achieved by reducing the collimator margin
from 7 mm to 2 mm, because the resulting reduction in relative
dose coverage of the PTV was more than compensated by an
Fig. 3. (a) Variation in isotoxic absolute planning target volume
(PTV) D99 dose versus collimator margin for all patients
(numbered as in Table 1); data for patients 1-3 with smaller PTV
are shown as gray lines. (b) Means (and 1 standard equivalent
of the mean confidence intervals) of paired differences between
D99 for each margin and the 7-mm margin reference plan for all
12 patients. Maximum and minimum D99 differences for each
collimator margin are shown as gray dashes. (c) Mean paired
differences, 1 standard equivalent of the mean confidence in-
tervals, and maximum and minimum D99 values for patients 4-12.
Fig. 4. Gross tumor volume (GTV) and planning target volume
(PTV) doseevolume histograms computed for the GTV located in
4 different positions (a-d) within the static phantom shown in
Figure 1.
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racy must be sufficiently accounted for by movement margins
when applying tighter collimator margins. We carried out a
phantom study to explore the impact of changing lung density
and of using a smaller dose calculation grid. In all cases, the
same optimum collimator margin of 2 mm achieved the best
absolute PTV dose coverage assessed via the D99 metric,optimally balancing isotoxically prescribed doses against rela-
tive PTV coverage.
Changes in dose may result from variations in the distribution
of mass density within the PTV caused by tumor movement
between different phases of the breathing cycle. A more rapid
buildup of dose in the GTV than in the surrounding lung causes
the dose to track the tumor, although previous studies based on
phantom measurements, 4D-CT images, and dose accumulation
techniques have found that this effect is small (16-18). Conse-
quently, PTV coverage calculated on a single CT dataset with a
single GTV position may marginally underestimate the real dose
accumulated over the respiratory cycle, because dose coverage at
the extremes of tumor movement is slightly higher than that
calculated for a fixed central position. Our phantom-based cal-
culations confirm that tumor movement does not result in any
deterioration in PTV coverage; differences in location of the GTV
within the PTV proved to have little impact (<1%) on doses
delivered to the PTV, even when a 2-mm margin was used.
Monte Carlo dosimetric analyses of SBRT treatments of lung
cancer suggest that optimal collimator margins lie in the range 0 to
5 mm (9, 19). The optimum collimator margin may depend on the
algorithm used to compute dose; however, we obtained the same
optimal margin using both the AAA and the AXB algorithms,
AXB being more accurate, particularly at the lung-tumor interface
(11, 20, 21).
One limitation of this study is that in order to focus on the
tradeoff between lung dose and tumor coverage, we did not
initially consider constraints on doses delivered to other organs at
risk. In practice, the steeper dose gradients outside the PTV
created by the tight 2-mm collimator margin also usefully reduce
doses to other normal structures (eg, cord) lying close to the target
volume. The IDEAL-CRT cord dose limit was reached before the
isotoxic lung dose limit for 3 of the 12 patients studied when a 7-
mm collimator margin was used, precluding dose escalation;
however, when a 2-mm margin was used, these patients’ pre-
scribed doses could be increased by 6.6 to 14.8 Gy.
Conversely, it is important to note that because doses in plans
created by use of wider collimator margins decrease more gently
around the PTV, these plans will be less sensitive to any dimi-
nution in target coverage that may result from target localization,
MLC positioning, or beam modelling uncertainties. Therefore,
Table 2 PTV coverage for the static phantom, achieved using 7-mm and 2-mm collimator margins and tabulated for different GTV
positions within the PTV for the AAA and AXB dose algorithms
Simulated
position GTV movement
7-mm margin
AAA, D99 (%)
2-mm margin
AAA, D99 (%)
7-mm margin
AXB, D99 (%)
2-mm margin
AXB, D99 (%)
Mid Center 92.7 85.8 91.5 84.9
Exhale þ10 mm cranial 92.4 85.5 91.0 84.6
Inhale and post 15 mm caudal
and 5 mm post
93.1 85.8 90.7 84.0
Inhale 15 mm caudal 93.2 86.0 91.4 84.8
Max diff 0.8% 0.5% 0.8% 0.9%
Abs diff (Gy) 0.54 0.34 0.54 0.61
Abbreviations: AAA Z anisotropic analytical algorithm; AXB Z Acuros; GTV Z gross tumor volume; PTV Z planning tumor volume.
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patient movement and setup margins are included in the planning
process.
Conclusions
For isotoxically prescribed conformal treatments of NSCLC,
absolute dose coverage of the PTVassessed by the D99 metric may
be maximized by using of smaller collimator margins than are
usually applied in treatment planning for lung cancer. In practice,
these narrower collimator margins reduce relative PTV coverage
by around 7%, and they should therefore be used only if gains at
least this great can be achieved in prescribed dose: for IDEAL-
CRT a 7-mm collimator margin should be used to treat patients
eligible for the maximum 73-Gy dose because narrower margins
reduce the PTV coverage while failing to raise the prescribed
dose.
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